REBLOZYL 75mg 50mg/ml powder for solution for injection BRISTOL MYERS SQUIBB ORIGINAL MEDICINE
Chemical substance: luspatercept
ATC code: B03XA06 • Blood and blood forming organs | Other antianemic preparations
Active substance
Results for the substance luspatercept
2 results
About this active substance
Luspatercept is a medication used for the treatment of anemia associated with myelodysplastic syndromes and beta-thalassemia. It works by regulating erythrocyte maturation, increasing red blood cell production.
The medication is administered as a subcutaneous injection, usually once every three weeks, under the supervision of a specialist. Regular monitoring of hemoglobin levels is important during treatment.
Side effects may include fatigue, bone pain, high blood pressure, or injection site reactions. In rare cases, severe allergic reactions may occur.
Luspatercept is not recommended for patients with hypersensitivity to this medication or for pregnant women, as it may affect fetal development.
The medication is administered as a subcutaneous injection, usually once every three weeks, under the supervision of a specialist. Regular monitoring of hemoglobin levels is important during treatment.
Side effects may include fatigue, bone pain, high blood pressure, or injection site reactions. In rare cases, severe allergic reactions may occur.
Luspatercept is not recommended for patients with hypersensitivity to this medication or for pregnant women, as it may affect fetal development.
-
-
REBLOZYL 25mg 50mg/ml powder for solution for injection BRISTOL MYERS SQUIBB ORIGINAL MEDICINE
Chemical substance: luspatercept
ATC code: B03XA06 • Blood and blood forming organs | Other antianemic preparations